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An early event in lung oncogenesis is loss of the tumour suppressor gene LIMD1 (LIM domains containing 1); this encodes a scaffold
protein, which suppresses tumorigenesis via a number of different mechanisms. Approximately 45% of non-small cell lung cancers
(NSCLC) are deficient in LIMD1, yet this subtype of NSCLC has been overlooked in preclinical and clinical investigations. Defining
therapeutic targets in these LIMD1 loss-of-function patients is difficult due to a lack of ‘druggable’ targets, thus alternative
approaches are required. To this end, we performed the first drug repurposing screen to identify compounds that confer synthetic
lethality with LIMD1 loss in NSCLC cells. PF-477736 was shown to selectively target LIMD1-deficient cells in vitro through inhibition
of multiple kinases, inducing cell death via apoptosis. Furthermore, PF-477736 was effective in treating LIMD1−/− tumours in
subcutaneous xenograft models, with no significant effect in LIMD1+/+ cells. We have identified a novel drug tool with significant
preclinical characterisation that serves as an excellent candidate to explore and define LIMD1-deficient cancers as a new
therapeutic subgroup of critical unmet need.
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INTRODUCTION
Lung cancer remains the most common cancer in the Western
world with ~2 million cases reported worldwide each year [1]. The
most frequent type of lung cancer is non-small cell lung cancer
(NSCLC), accounting for 84% of total cases, the majority of which
are either lung adenocarcinomas (LUAD) or lung squamous cell
carcinomas (LUSC) [1, 2]. The 5-year survival of lung cancer
patients is only 19%, with minimal improvement in the past 30
years. Recent breakthroughs in immunotherapies and immune
checkpoint blockade for lung and several other cancers is
encouraging [3–5]. Furthermore, advances in targeted therapy
has led to the advent of highly specific targeted treatments, such
as tyrosine kinase inhibitors [6]. When used in combination with
immunotherapy, this has achieved significant survival benefit for
select patient subgroups [7]. However, only a proportion of
patients will benefit (~10–40% depending on cancer type), with
the overall survival rates remaining largely unchanged [8–12]. This
highlights the clear need for novel biomarkers and improved
targeted therapies that effect wider patient populations beyond
those aided by current approaches [13]. Furthermore, the plethora
of mechanisms underlying lung cancer development and
progression still remain largely unknown. Driver alterations have
not yet been defined in ~40% of lung cancers. Although
mutations in several well-known oncogenes and tumour suppres-
sor genes have been detected in certain lung cancers, a large
proportion of patients do not contain these common truncal
mutations [14–17]. An improved understanding of lung cancer
drivers and enhanced treatment options are urgently needed.
LIMD1 (LIM domains containing 1) is a tumour suppressor gene
encoded at the 3p.21.3 genomic locus, which is frequently ablated
early in lung cancer development. Reduced LIMD1 copy number
alterations in LUAD correlate with poor patient prognosis [18].
Furthermore, LIMD1−/− mice develop increased numbers and
larger volumes of lung adenomas following exposure to the
carcinogen urethane or upon crossing with KRASG12D mice,
highlighting loss of LIMD1 as a major driver in lung cancer and
potential LUAD and LUSC susceptibility gene [18, 19]. Human lung
cancers deficient in LIMD1 expression represent 50% and 85% of
LUAD and LUSC, respectively [18], and have been completely
overlooked in preclinical studies. This biomarker signifies a new
and exciting avenue for investigation in lung cancer biology and
importantly a novel treatment strategy for LIMD1-deficient
tumours.
LIMD1 is a member of the Zyxin family of LIM-domain proteins,
which feature three tandem LIM domains at the C-terminus that
facilitates protein-protein interactions and an unstructured
N-terminal pre-LIM region [20]. Whilst LIMD1 has no enzymatic
function, it plays an important role in modulating many essential
homoeostatic processes by operating as a molecular scaffold
[18, 21–29]. We have shown a critical role of LIMD1 as a core
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component of the microRNA-induced silencing complex (miRISC)
[24], and in regulating the hypoxic response by mediating efficient
degradation of HIF-1α through simultaneous binding of HIF prolyl-
hydroxylases and the Von-Hippel Lindau protein (pVHL) [23, 30]. In
addition, LIMD1 binds to and enhances the function of the
retinoblastoma protein (pRB), thereby acting as a corepressor
blocking E2F1-driven gene transcription and subsequent cell cycle
progression [21]. Loss of LIMD1 and its multiple tumour
suppressive functions lead to alterations and disruption of these
key regulatory pathways, driving cellular transformation and
cancer progression.
Despite LIMD1’s key homoeostatic functions, the level of
ablation in LUAD/LUSC and the large disease burden in lung
cancer, there are currently no targeted therapies for LIMD1-
deficient cancers. Defining therapeutic targets in these LIMD1 loss-
of-function patients is difficult due to no clear ‘druggable’
enzymes that can be targeted, meaning alternative approaches
are required. This is further complicated due to the number of
diverse pathways impacted upon loss of LIMD1, therefore
targeting downstream pathways in isolation is not a feasible
option. The concept of synthetic lethality provides a rationale for
targeting loss of tumour suppressor genes; whereby cellular
vulnerabilities acquired following loss of tumour suppressors are
exploited to induce cell death in tumour verses normal tissue. The
prime example of this is the use of PARP inhibitors in BRCA1
mutant cancers, which is now an approved targeted therapy in
several cancers [31].
To this end, we have performed the first proof-of-concept drug
repurposing screen to identify synthetically lethal compounds
with LIMD1 loss. Drug repurposing is an attractive option as a
significant amount of preclinical data and safety profiling have
already been generated for these compounds, allowing expedited
clinical trials for alternative indications [32].
From our compound library screen, we identified a multi-kinase
inhibitor, PF-477736 that selectively kills LIMD1-negative cells
compared to LIMD1-proficient cells. Whilst this inhibitor was
designed as a checkpoint kinase 1 (Chk1) inhibitor, we have
shown that Chk1 inhibition does not confer the synthetic lethal
interaction with LIMD1 loss in these cells. Instead, our data
indicate that this inhibitor affects a broad spectrum of kinases,
inducing significant changes to the phosphoproteome specifically
in LIMD1-negative cells. Finally, we show that this inhibitor has
therapeutic potential in LUAD. This study provides proof-of-
concept that LIMD1 expression can be used as a stratification
marker for treatment, identifying a large group of lung cancer
patients that could benefit from a targeted therapy against
LIMD1 loss.
RESULTS
Drug repurposing screen identified PF-477736 as selective
inhibitor of LIMD1−/− cells
To identify compounds that selectively target LIMD1−/− cells, we
screened CRISPR-Cas9-generated isogenic LIMD1+/+ and LIMD1−/−
HeLa cells with a compound library of 485 small molecules. This
drug library was collated to include FDA-approved drugs, clinical
candidates and compounds against known cancer pathways
[33, 34]. Cells were treated with a 1 μM concentration of each
compound, and cell viability was determined after 4 days. Upon
determination of the ΔZ-scores we identified the Chk1 inhibitor PF-
477736 as our lead hit, as it had one of the highest ΔZ-scores,
causing significantly decreased cell viability in LIMD1−/− cells,
compared to the LIMD1+/+ cells, as well as not showing overt
toxicity in the LIMD1+/+ line (Fig. 1A). We validated this synthetic
lethal interaction across a range of concentrations, in multiple
LIMD1−/− cell clones (Fig. 1B–E). Of note, this phenotype was
validated in our isogenic pair of CRISPR-Cas9-generated LUAD
A549 LIMD1+/+ and LIMD1−/− cells (Fig. 1E) indicating this effect
was not cell line specific and was relevant in the context of lung
cancer biology. In both LIMD1 isogenic cell models, there was a ~2-
fold selectivity towards LIMD1−/− cells compared to LIMD1+/+
controls (Fig. 1D, E) demonstrated by a significant difference in
SF50 values (Fig. S1A, B). In addition, we validated this effect in the
clear-cell renal cell carcinoma cell line RCC48, using RNAi depletion
of LIMD1. Here we observed increased sensitivity of these shLIMD1
cells to PF-477736 treatment, which could be rescued upon the
expression of an RNAi-resistant Flag-His-tagged LIMD1 indicating
that this increased sensitivity is specific to LIMD1 loss (Fig. S1C). We
further validated this effect using long-term clonogenic drug
assays in A549 and HeLa cells, which showed a significant decrease
in clonogenic potential for LIMD1−/− cells compared to the
LIMD1+/+ upon PF-477736 treatment (Figs. 1F, G and S1D, E). In
addition, we treated these isogenic lines with 1 μM PF4 and
measured cell proliferation using bright field imaging on Incucyte
Zoom; whilst there was a modest reduction in proliferation in the
LIMD1+/+ lines upon PF-477736 treatment (~1.6-fold reduction in
AUC), this effect was significantly enhanced in both LIMD1−/−
clones (~7-fold reduction in AUC) (Fig. 1H). Notably, PF-477736
treatment induced ‘blebbing-like’ structures of cell membranes in
LIMD1−/− cells, suggesting that cells may be undergoing increased
apoptosis (Fig. S1F). This was confirmed by increased PARP
cleavage and caspase activation in LIMD1−/− clones compared to
LIMD1+/+ controls upon PF-477736 treatment (Figs. 1I, J and
S1G–J). Annexin V staining identified the increased early and late
apoptotic cell populations in PF-477736 treated LIMD1−/− cells
(Fig. S1K). Taken together, these data indicate that PF-477736
treatment can selectively target LIMD1−/− and RNAi-driven
deficient cells; identifying apoptosis as the mechanism of cell
death.
PF-477736 selectively kills LIMD1−/− cells independent of
Chk1 inhibition
PF-477736 was originally developed for use in combination
therapy with DNA damage-inducing agents as a sub-nanomolar
ATP-competitive inhibitor of Chk1 (Ki= 0.49 nM) [35]. However,
neither of the two Chk1 inhibitors in the compound library
(AZD7762 and LY2603618) were identified as hits in the screen
(Fig. S2A). We reasoned this may have been an artefact of the
single-concentration dose used in the primary screen. We tested
an alternative Chk1 inhibitor, SCH900776 (MK-8776, Chk1 Ki=
3 nM), to establish if this caused LIMD1−/−-specific cell death
(Fig. 2A, B). We did not observe any difference in cell viability upon
SCH900776 treatment between our HeLa LIMD1 isogenic lines.
Transient RNAi knockdown of CHEK1 in our isogenic lines was also
performed, and once again did not induce any differences in cell
viability between these lines (Fig. 2C, D). These data indicate that
Chk1 inhibition is not synthetically lethal with LIMD1 loss, and
therefore the effects we see with PF-477736 are likely to be
through off-target inhibition of an alternative kinase or kinases.
PF-477736 is a broad-spectrum kinase inhibitor that elicits
LIMD1−/−-specific cellular changes in the phosphoproteome
With the aim of identifying the kinase inhibited by PF-477736 that
is responsible for the observed synthetic lethality with LIMD1 loss,
we tested the activity of PF-477736 on a panel of 403 recombinant
non-mutant kinases and 59 clinically relevant disease-mutant
kinases using the DiscoverX KINOMEscan platform, which involves
an in vitro ATP-independent competition assay to measure kinase
activity [36]. Optimum inhibitor concentration is defined as 3–10-
fold higher than the Ki of targeted interactions, therefore as in
cellulo we observe the strongest synthetic lethal interaction at
1 μM, we opted to perform profiling at a concentration of 3 μM.
Surprisingly, 303 out of the 468 kinases tested were inhibited by
over 50%, upon PF-477736 treatment compared to the DMSO
control (Fig. 3A). We observed a wide range of inhibition across
the kinases tested, with 18.4% of kinases inhibited by 99%, further
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highlighting the broad specificity of this inhibitor (Fig. 3B). A
percentage of control value of <1% indicates a Kd value of <30 nM.
Chk1 activity was reduced to 0.45% by PF-477736, and a number
of other kinases were more potently inhibited than Chk1 (Fig. 3C).
Next, in an endeavour to elucidate which kinases are inhibited by
PF-477736 in the cell as opposed to the in vitro study, we analysed
the phosphoproteome in our isogenic lines upon drug treatment.
Following 1 h treatment with PF-477736 we did not observe any
significant changes in the phosphoproteome of HeLa LIMD1+/+
cells; strikingly however, there were numerous significant changes
K. Davidson et al.
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occurring in the HeLa LIMD1−/− cells (Fig. 3D). Principal
component analysis (PCA) on these data showed no separation
between treated and untreated samples in the LIMD1+/+ cell line,
but a clear separation in the LIMD1−/− cell line (Fig. S3A, B). This
result emphasises that PF-477736 treatment elicits significant
phosphorylation changes specifically upon loss of LIMD1. We next
utilised kinase-substrate enrichment analysis (KSEA) to infer kinase
activities from our quantitative phosphoproteomics data [37]. This
analysis identified a number of kinases (CK2A1, CDK1, PKCA, ERK1
and Akt1) that were significantly more active in LIMD1−/− cells
compared to LIMD1+/+ controls (Fig. S3C). Furthermore, CK2A1,
PKCA and Akt1 were all significantly inhibited following PF-477736
treatment specifically in LIMD1+/+ cells. Interestingly, LIMD1+/+
cells exhibited increased CK2A1 activity after treatment (Fig. 3E). In
our DiscoverX KINOMEscan data, these kinases were inhibited by
90.1%, CK2A1; 89%, PKCA and 77%, Akt1 (Fig. 3A–C). To determine
whether loss of these kinases could induce synthetic lethality upon
LIMD1 loss, we knocked down the expression (via siRNA) of these
kinases in combination, however, there were no significant
changes in cell viability between our isogenic lines with each of
these knock-downs (Fig. S3D). We next reasoned that knocking
down the kinase levels significantly with siRNA could possibly still
leave very low levels of protein and activity that could still maintain
viability, and thus opted to examine small-molecule inhibitors
against the targets (both individually and in combination at a dose
that corresponds with SF80). This drug-targeted approach was
based on inhibitors: MK-2206, AKT inhibitor; Silmitasertib, a casein
kinase 2 inhibitor; and Gouml 6983 (Go-6983), a broad-spectrum
PKC inhibitor. These drug combinations did not show any
selectivity towards LIMD1-deficient cells, indicating that other
pathways are involved (Fig. S3E, F). Regardless of not identifying a
specific kinase or pathway inhibited by PF-477736 in LIMD1-
deficient cells, these data do indicate that loss of LIMD1 increases
the activity of a broad panel of kinases including CK2A1, PKCA and
Akt1, which were collectively inhibited by PF-477736 treatment
leading to increased apoptosis in LIMD1−/− cells.
Fig. 1 PF-477736 is a selective inhibitor of LIMD1-deficient cells. A Waterfall plot of ΔZ-Scores from compound library screen. Isogenic
LIMD1−/− and control lines were treated with a 1 µM dose and cell viability measured after 4 days (n= 3). B, C Immunoblot of CRISPR-Cas9-
generated LIMD1−/− HeLa and A549 cell lines. D, E Dose–response curves of PF-477736 in A549 and HeLa isogenic LIMD1−/− lines. Cells were
drugged twice over 4 days before measuring cell viability and calculating surviving fraction (n= 3). F, G Colony formation assay of A549
isogenic LIMD1−/− cells following treatment of PF-477736 for 10 days. Cells were treated every 2 days with indicated concentration of PF-
477736 before fixation and staining (n= 3, two-way ANOVA). H Growth of HeLa isogenic LIMD1−/− measured using Incucyte Zoom following
1 µM treatment with PF-477736 (n= 3; one-way ANOVA comparing AUC for each curve). I Western blot of PARP and caspase cleavage in HeLa
isogenic LIMD1−/− lines treated with PF-477736 for 48 h (n= 4). J Quantification of western blot of apoptosis markers in HeLa isogenic
LIMD1−/− lines treated with PF-477736 for 48 h (n= 4, two-way ANOVA). ns p > 0.05, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.
Fig. 2 PF-477736 selectively kills LIMD1−/− cells independent of Chk1 inhibition. A Dose–response curve of SCH900776 in HeLa isogenic
LIMD1−/− lines. Cells were treated for 4 days before measuring viability and calculating surviving fraction (n= 3). B Bar chart of SF50 values
from panel (A) (n= 3, one-way ANOVA). C Surviving fraction of HeLa isogenic LIMD1−/− lines transfected with siRNA against CHEK1 at 50 nM
and 20 nM for 72 h (n= 3, two-way ANOVA). ns p > 0.05. D Immunoblot of Chk1 and LIMD1 in HeLa isogenic LIMD1−/− lines transfected with
siRNA against CHEK1 (20 nM, 72 h) (n= 3).
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PF-477736 treatment as an initial proof-of-concept inhibitor
of LIMD1-deficient lung cancers
Previous work from our group has extensively characterised the
role of LIMD1 as a tumour suppressor in lung cancer, therefore we
investigated the potential of PF-477736 as a therapeutic option
against LIMD1-deficient lung cancer cell lines. We have already
shown selectivity of PF-477736 against LIMD1−/− A549 cells, a
NSCLC adenocarcinoma cell line (Fig. 1E). To test PF-477736 in non-
transformed lung cells, we generated LIMD1−/− small airway
epithelial cells (SAEC) that had been immortalised by overexpres-
sing Bmi1 (SAEC-Bmi1). These SAEC are a mixture of both type I and
type II alveolar cells, thereby serving as an appropriate model of
LUAD progenitor cells, which have been CRISPR-Cas9 edited to
express a N-terminal truncated form of LIMD1 in significantly lower
levels compared to non-targeting controls, thereby representing an
in vitro model of LIMD1 loss in the development of adenocarci-
noma (Fig. 4A). Comparable with our other isogenic cell lines, we
observed ~2–4-fold selectivity for SAEC LIMD1−/− cells (Fig. 4B).
Next, we treated a panel of LUAD cell lines exhibiting a range of
LIMD1 protein expression levels, with PF-477736 at 1 μM (Fig. 4C, D).
We observed a significant positive correlation (Pearson’s
correlation coefficient= 0.579, p= 0.0302) with LIMD1 protein
expression and surviving fraction, thereby indicating that it may
be possible to use LIMD1 expression as a biomarker to stratify
patients for targeted therapy treatment efficacy (Fig. 4D). To test
the efficacy of PF-477736 in vivo, we inoculated NOD/SCID mice
with our A549 isogenic lines subcutaneously and treated with PF-
477736 twice on indicated days. LIMD1+/+ tumours were
unaffected by PF-477736 treatment in vivo, however we observed
a significant decrease in tumour growth in the LIMD1−/− tumours
upon treatment (Figs. 4E and S4A, B). Staining of these tumours
with markers for cell proliferation (Ki67, Figs. 4F and S4C) and
apoptosis (cleaved caspase-3, Figs. 4G and S4D), revealed that
PF-477736 selectivity inhibits proliferation in LIMD1-deficient lung
xenografts and increases apoptosis within these tumours, in
agreement with our in vitro data.
To summarise our results, we have identified that PF-477736
selectively induces apoptosis in LIMD1−/− cells by targeting
multiple susceptibility pathways, whilst sparing LIMD1+/+ cells.
This is the first evidence supporting a targeted therapeutic
approach for the treatment of lung cancers with reduced or loss of
LIMD1 expression.
Fig. 3 PF-477736 is a broad-spectrum kinase inhibitor that elicits LIMD1−/−-specific cellular changes in the phosphoproteome.
A Heatmap showing remaining kinase activity of a panel of in vitro kinases upon 3 µM PF4-77736 treatment in DiscoverX KINOMEscan assay.
B Venn diagram representing the proportion and number of kinases inhibited to less than 35%, 10% and 1% of control activity. C Waterfall
plot of kinases most inhibited by PF-477736 (3 µM) in the in vitro kinase assay. D Volcano plot of phosphosite changes between 1 µM PF-
477736-treated and DMSO control lysates in isogenic HeLa lines. Cells were harvested following 1 h drug treatment. No significant
phosphosite changes were induced by PF-477736 in the LIMD1+/+ cell line, compared with 54 reduced and 119 increased phosphosites in the
LIMD1−/− cell line. Cut-off point for statistically significant phosphosite is a false discovery rate of >0.05 and S0 of 0.01 (n= 3). E Kinase
substrate enrichment analysis (KSEA) of phosphoproteomics shows kinases significantly affected by PF-477736 treatment in LIMD1+/+ (grey)
or LIMD1−/− cells (green) *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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DISCUSSION
Lung cancer has a staggering disease burden, with a clear need for
targeted therapies that are effective in wider patient populations.
Treating/targeting the loss of the tumour suppressor gene LIMD1
is an attractive therapeutic option as we have identified copy
number alterations in ~47% of LUAD patients [18]. Here we show
a proof-of-concept study identifying PF-477736 as a selective
inhibitor of LIMD1-deficient cells (Fig. 1). Crucially, we observe a
correlation with LIMD1 expression and drug sensitivity, indicating
that we may be able to use LIMD1 expression as a biomarker for
new targeted therapies, and thus indicate potential treatment
response.
PF-477736 is a Chk1 inhibitor, however our results indicate a
large number of kinases are potently inhibited in vitro and in
cellulo by PF-477736 (Fig. 3). This finding is perhaps not surprising,
as an expanding number of studies have shown that several ATP-
pocket kinase inhibitors that have been used in clinical trials
exhibit off-target mechanisms of action distinct from the primary
drug target [38]. Our data suggest that targeting multiple
pathways is required to target LIMD1−/− cells; previous work
from our group and others have highlighted a number of
pathways that LIMD1 plays a critical role in regulating [24, 39].
Therefore, it is unsurprising that targeting just one LIMD1-
regulated pathway is insufficient to recapitulate PF-477736-
induced cell death. Broad-spectrum inhibitors have been success-
fully utilised in other cancers, such as dual inhibition of PDGFRa
and FGFR2 by pazopanib in SMARCB1-deficient rhabdoid tumours
[40, 41]. This fits within our model of LIMD1 being a nodal gene,
loss of which re-orchestrates numerous homoeostatic cellular
pathways, which requires inhibition of multiple deregulated
pathways to induce cell death. For our analysis we focused on
protein kinases as PF-477736, which was designed as an inhibitor
Fig. 4 PF-477736 treatment is proof-of-concept inhibitor of LIMD1-deficient lung cancers. A Immunoblot of isogenic LIMD1−/− small
airway epithelial cells (SAEC) and control. B Dose–response of PF-477736 in isogenic LIMD1−/− SAEC. Cells were treated twice prior to
measuring cell viability and calculating surviving fraction (n= 3). C Immunoblot of LIMD1 in a panel of lung adenocarcinoma cell lines
(representative blot from n= 3). D Pearson’s correlation coefficient between LIMD1 protein expression and surviving fraction of indicated cell
line after treatment with 1 µM PF-477736. E Relative tumour growth of subcutaneous A549 isogenic xenografts implanted into the flank of
NOD/SCID mice. Mice were treated twice on indicated days with vehicle or PF-477736 (7.5 mg/kg per dose) (n= 10 per group).
F, G Immunohistochemical staining and scoring of Ki67 (F) and cleaved caspase-3 (G) in mouse xenograft tumours (n= 10 per group, two-way
ANOVA).
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of the ATP moiety to block kinase function, however, there
remains the possibility that PF-477736 is acting on a non-kinase
enzyme or a kinase not covered by our analysis.
This proof-of-concept study has identified, for the first time, a
selective inhibitor of LIMD1-deficient cells. We have shown that it
is possible to target these cells with a small molecule, allowing for
the potential targeted treatment of a large proportion of lung
cancer patients with LIMD1-deficient tumours. Targeting such
cancers is particularly attractive as LIMD1 loss has been further
observed in breast, cervical, gastric, renal, and head and neck
cancers [42–47]. Our study has identified a novel therapeutic
strategy based on LIMD1 status, which exploits the loss of this
tumour suppressor, offering the potential for targeted treatment




Cells were maintained in DMEM (HeLa, A549) or RPMI (HCC193, H1299,
Hop62, H358, H838, H358M, H2887, H522, H322M, H23, MOR, H3122)
(Sigma) supplemented with 10% FCS and 1% penicillin/streptomycin
solution in a humidified 37 °C incubator with 5% CO2. SAEC were
maintained in complete Airway Epithelial Cell Medium (ATCC). SAEC cells
were immortalised using pFLRu-Bmi-1. Parental stocks of each line were
obtained from ATCC. All cell cultures were regularly tested for
mycoplasma. Isogenic lines were authenticated by STR profiling post
editing.
Drug screen
Cells were plated in 96-well plates at an optimised cell density, and after
24 h, treated with vehicle (0.01% DMSO) or the compound library at a final
concentration of 1 μM. Cells were dosed again after 48 h. Cell viability was
assessed using CellTitre-Glo (Promega) after 4 days of drug exposure,
according to manufacturer’s instructions. Luminescence readings from
each well were log transformed and normalised according to the median
signal on each plate and then standardised by Z-score statistic, using the
median absolute deviation to estimate the variation in each screen. Z-
scores were compared to identify compounds that cause selective loss of
viability in LIMD1−/− cells compared to LIMD1+/+ cells.
Drug validation experiments
PF-477736 was provided by Pfizer as part of Pfizer Global Medicine Grant
60411717. SCH900776, MK-2206 Go-6983, Silmitasertib were purchased
from Selleckchem. In line with the drug-screen protocol, cells were seeded
into a 96-well plate and treated 24 h later with a concentration range of
drug, or DMSO control. Cells were re-dosed with the drug after 48 h and
cell viability was determined after 4 days of drug exposure using CellTitre-
Glo. For combination studies, SF80 was calculated using the formula SF80=
(80/(100− 80)√Hill slope) × SF50. Cells were plated and dosed as above
before measuring viability with CellTitre-Glo.
Colony formation assay
Cells were seeded at 1000 cells per well in 6-well plates. At 24 h post
seeding, cells were treated with drug or vehicle control. Drug-containing
media was refreshed every 2 days and cells were fixed in methanol after
10 days of treatment. Colonies were stained with 0.05% crystal violet and
counted manually or total colony area was calculated using ImageJ.
Incucyte
Growth curves were generated using the Incucyte ZOOM live-cell imaging
platform (Essen Bioscience). Cells were seeded into 96-well plates and were
drugged 24 h later with either 1 μM PF-477736 or DMSO control. Images
were captured at 10x magnification on the Incucyte every 2 h. Drug was
refreshed after 68 h. Cell confluence per well was calculated using the
Incucyte ZOOM software (Essen Bioscience).
Protein analysis
Cell pellets were lysed in RIPA buffer (150 nM NaCl, 1% (v/v) IGEPAL, 0.5%
(w/v) deoxycholic acid, 0.1% (w/v) SDS, 50 mM Tris) supplemented with
protease and phosphatase inhibitors. Protein was quantified using the
Pierce BCA protein assay kit (Thermo Fisher Scientific). Lysates were
electrophoresed on acrylamide gels of appropriate acrylamide percentage,
transferred onto PVDF membranes and immunoblotted using the
following antibodies: LIMD1 (in house), β-actin (Sigma #A1978), Total
PARP (CST #9532), Cleaved PARP (CST #6704), Caspase 7 (CST #12827),
Caspase 9 (CST #9508), Caspase 3 (CST #9668) and Cleaved Caspase 9 (CST
#7237), Chk1 (CST #2360). Anti-IgG horseradish peroxidase (Dako) and
chemiluminescent detection (Thermo Fisher Scientific) were used to
develop immunoblots.
siRNA transfections
siRNA targeting Chk1, CSNK2A1, AKT1, PKCA, PLK1 and non-targeting
control were obtained as SMARTPools from Dharmacon. siRNAs were
transfected using Lipofectamine RNAiMax (Invitrogen) according to
manufacturer’s instructions. Then, 96-well plates were used for cell viability
endpoints, and 12-well or 6-well plates were used for protein extraction to
determine the protein knockdown by immunoblot.
Annexin V staining
Cells were seeded into 10 cm dishes at a density of 1 × 104 cells/dish; 24 h
later, dishes were treated with 1 μM PF-477736 or DMSO vehicle control.
After 48 h, cells were trypsinised, harvested (including those in media and
PBS washes), counted and 1 × 106 cells were resuspended into 1x annexin-
binding buffer (Thermo Fisher Scientific). Then, 2 μL Alexa Flour 488
Annexin V (Thermo Fisher Scientific) and 1 μL 100 μg/mL PI were added to
each 100 μL of cell suspension and incubated for 15min. Single-stained
and unstained controls were stained accordingly. Samples were run
through the BD LSR Fortessa flow cytometer (Becton Dickinson, USA),
recording 10,000 events for each sample. Data were analysed using FlowJo
version 10 (FlowJo LLC).
Kinase profiling
Kinase profiling was conducted by DiscoverX (USA). PF-477736 was
dissolved in DMSO and diluted to 3mM (1000x screening concentration)
for shipment. Profiling was performed by Discover X as per their in-house
protocols.
Phosphoproteomics
Mass spectrometry analysis was conducted as described by Casado et al.
(2018) [48]. Briefly, HeLa LIMD1+/+ and LIMD1−/− were seeded into 10 cm
dishes at 7 × 105 cells/dish. At 48 h post seeding, dishes were treated with
either 1 μM PF-477736 or DMSO vehicle control for 1 h. Cells were washed
3x in ice-cold PBS containing protease and phosphatase inhibitors (1 mM
NaF and 1mM Na3VO4). Dishes were lysed in 200 μL of lysis buffer (8 M
urea in 20mM HEPES (pH 8.0) supplemented with 1mM Na3VO4, 1 mM
NaF, 1 mM β-glycerol phosphate and 2.5 mM Na2H2P2O7) and cells were
scraped and transferred into Protein LoBind tubes (Eppendorf). Samples
were sonicated for 10 cycles (30 s on and 40 s off) in a Diagenode
Bioruptor® Plus. Samples were centrifuged at 20,000g for 10 m, 4 °C and
supernatant was transferred to 1.5 mL Protein LoBind tubes. BCA assay was
conducted to quantify protein concentration.
Protein suspensions of 400 µg of protein in a volume of 200 µL were
subjected to cysteine reduction and alkylation using sequential incubation
with 10mM dithiothreitol (DDT) and 16.6 mM iodoacetamide (IAM) for 1 h
and 30min, respectively, at 25 °C with agitation. The urea concentration in
the protein suspensions was reduced to 2M by the addition of 600 µL of
20mM HEPES (pH 8.0), and 100 μL of equilibrated trypsin beads were
added and samples were incubated overnight at 37 °C. Trypsin beads (50%
slurry of TLCK-trypsin) were equilibrated with 3 washes with 20mM HEPES
(pH 8.0). The following day, trypsin beads were removed by centrifugation
(2000g at 5 °C for 5 min) and samples were desalted using Oasis HLB
cartridges (Waters).
Briefly, cartridges set in a vacuum manifold device, with a pressure
adjusted to 5mmHg, were conditioned with 1mL acetonitrile (ACN) and
equilibrated with 1.5 mL of wash solution (0.1% trifluoroacetic acid (TFA),
2% ACN). Then, peptide solutions were loaded into the cartridges and
washed twice with 1 mL of wash solution. Peptides were eluted with
0.5 mL of glycolic acid buffer A (1 M glycolic acid, 5% TFA, 50% ACN).
For phosphopeptide enrichment, eluents were normalised to 1 mL with
glycolic acid buffer B (1 M glycolic acid, 5% TFA, 80% ACN) and incubated
with 25 µL of TiO2 solution (500mg TiO2 beads in 500 µL of 1% TFA) for
5 min at room temperature (RT). TiO2 beads were packed by centrifugation
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into empty spin columns previously washed with ACN. TiO2-bead pellets
were sequentially washed by centrifugation (1500g for 3 min) with 100 µL
of glycolic acid buffer B, ammonium acetate buffer (100mM ammonium
acetate in 25% ACN) and twice with neutral solution (10% ACN). Spin tips
were transferred to fresh tubes, and phosphopeptides were eluted by
adding 50 µL of elution solution (5% NH4OH, 7.5% ACN) and centrifuging
the spin tips at 1500g for 3 min. This elution step was repeated a total of
four times. Finally, samples were frozen in dry ice for 15min, dried in a
SpeedVac vacuum concentrator and stored at −80 °C.
Peptide pellets were reconstituted in 13 µL of reconstitution buffer
(20 fmol/µL enolase in 3% ACN, 0.1% TFA) and 5 µL were loaded twice onto
an LC-MS/MS system consisting of a Dionex UltiMate 3000 RSLC coupled to
Q Exactive™ Plus Orbitrap Mass Spectrometer (Thermo Fisher Scientific)
through an EASY-Spray source. Chromatographic separation of the
peptides was performed using the mobile phases A (3% ACN; 0.1% FA)
and B (99.9% ACN; 0.1% FA). Peptides were loaded in a μ-pre-column and
separated in an analytical column using a gradient running from 3% to
23% B over 60min. The UPLC system delivered a flow of 2 µL/min (loading)
and 250 nL/min (gradient elution). The Q Exactive Plus operated a duty
cycle of 2.1 s. Thus, it acquired full scan survey spectra (m/z 375–1500) with
a 70,000 FWHM resolution followed by data-dependent acquisition in
which the 15 most intense ions were selected for HCD (higher-energy
collisional dissociation) and MS/MS scanning (200–2000 m/z) with a
resolution of 17,500 FWHM. A dynamic exclusion period of 30 s was
enabled with a m/z window of ±10 ppm.
Peptide identification was automated using Mascot Daemon 2.6.0. Thus,
Mascot Distiller v2.6.1.0 generated peak list files (MGFs) from RAW data and
Mascot search engine (v2.6) matched the MS/MS data stored in the MGFs
to peptides using the SwissProt Database (SwissProt_2016Oct.fasta).
Searches had a false discovery rate (FDR) of ~1% and allowed 2 trypsin
missed cleavages, mass tolerance of ±10 ppm for the MS scans and
±25mmu for the MS/MS scans, carbamidomethyl Cys as a fixed
modification and PyroGlu on N-terminal Gln, oxidation of Met and
phosphorylation on Ser, Thr and Tyr as variable modifications.
A label-free procedure based on extracted ion chromatograms (XICs)
quantified all identified peptides. Missing data points were minimised by
constructing XICs across all LC-MS/MS runs for all the peptides identified in
at least one of the LC-MS/MS runs [49]. XIC mass and retention time
windows were ±7 ppm and ±2min, respectively. Quantification of peptides
was achieved by measuring the area under the peak of the XICs. Individual
peptide intensity values in each sample were normalised to the sum of the
intensity values of all the peptides quantified in that sample. Data points
not quantified for a particular peptide were given a peptide intensity value
equal to the minimum intensity value quantified in the sample divided by
10. Significant differences in phosphopeptide intensities were assessed by
student’s t test with Benjamini Hochberg multiple testing correction (FDR).
Kinase-substrate enrichment analysis
Kinase-substrate enrichment analysis (KSEA) was conducted as previously
described by Casado et al. (2013) [37]. Briefly, phosphopeptides with a p <
0.05 (assessed by t test of log2-transformed data) were grouped into
substrate sets based on the PhosphoSite database. The ‘enrichment’
method was used to infer differences in the abundance of substrate
groups across samples. Z-score was calculated using the formula (Z-score
= (mS−mP)*m1/2/δ) where m is the size of the substrate group and δ is
the standard deviation of the mean abundance across the whole dataset.
Z-score was converted to a p value in Excel.
Immunohistochemistry and scoring
Formalin-fixed paraffin-embedded (FFPE) mouse tumours were sliced into
4 µm thick sections. Slides were baked overnight at 57 °C prior to dewaxing.
Afterwards, slides were put into xylene, 100% ethanol, and in 3% H2O2/
methanol solution for 10min for endogenous peroxidase inactivation.
Antigen retrieval for Ki67 and cleaved caspase-3 was done using a 10mM
citrate buffer (pH 6) for 10min at high power (700W) in a microwave.
Samples were left at RT for 30min and blocked in 10% goat serum for
20min. Primary antibodies (Ki67 Abcam ab16667, Cleaved Caspase-3 CST
#9661) were applied at a 1:100 dilution and left incubating for 1 h at RT
(Ki67) or overnight at 4 °C (cleaved caspase-3). Anti-rabbit biotinylated
secondary antibody (Vector laboratories BA-1000-1.5) was added at a 1:200
dilution for 30min at RT. Samples were incubated with ABC reagent (Vector
laboratories PK-6100) for 20min at RT. Afterwards slides were developed
with DAB solution (Dako K3468) for 5 min. Washes with PBS (2x, 2min each)
were carried out every time slides were incubated with a different reagent.
Finally, samples were counterstained with haematoxylin, differentiated
in 1% acid alcohol, dehydrated in 70%, 90% and 100% ethanol, cleared in
xylene and mounted using DPX mounting medium. Slides were imaged
using the PANNORAMIC 250 Flash III scanner (3D Histech).
For the scoring, ten 50x fields were selected at random so that the
tumour regions within the xenograph were uniformly covered. Cleaved
caspase-3-stained samples presented a highly apoptotic area at the
interphase of the tumour and the stromal regions. Cleaved caspase-3
staining was strong in this area for all samples (regardless of the cell type
or the treatment) and was therefore, excluded from the quantifications. For
Ki67, the quantification fields were imported into QuPath software and the
positive-cell-detection feature was used to detect the total number of cells
and the number of DAB-positive and -negative cells. For cleaved caspase-3,
ImageJ was used and positive cleaved caspase-3 cells were manually
counted using the Cell Counter plugin. Early and late apoptotic cells were
counted. Criteria for considering a cleaved caspase-3-positive cell was that
the DAB signal should show a defined shape and colocalise with
hematoxylin (presence of a nucleus). In some cases, a cell was included
where more than one nuclei was observed (late apoptosis).
Subcutaneous xenograft study
Six-week-old female NOD/SCID mice were purchased from Charles River
and housed with food and water ad libitum, five animals were kept in each
cage. A549 LIMD1−/− and LIMD1+/+ were grown until reaching the
beginning of the exponential growth phase and then detached and
resuspended in Matrigel 5 mg/mL (Sigma). First, 1 × 106 cells in 100 µL of
Matrigel were injected subcutaneously into the mice, 20 with A549
LIMD1−/− and 20 with A549 LIMD+/+. Tumour growth was measured three
times per week using callipers and the tumour size calculated using the
formula V= (length2 ×width)/2. Once the average tumour size was
between 150 and 200mm3, each group was randomised into two groups
to maintain equal tumour size between groups and once a week they
received either PF-477736 (7.5 mg/kg per dose) or vehicle (50 nM sodium
acetate and 4% dextrose, pH 4 (Sigma)) both dosed twice a day with 6 h
difference. Tumour size and mice weight were monitored three times per
week and the experiment was stopped when the tumour size exceeded
1.44 cm3. Mice were then culled and the tumours harvested, sectioned
longitudinally and each section was fixed in 10% neutral buffered formalin.
Statistical analysis
Data were normalised to relevant controls as required. Statistical analysis
was conducted using GraphPad Prism 8.0, using the appropriate statistical
test for the number of groups and type of data generated from the
experiment. All the data are shown as mean ± SD of a minimum of three
biological replicates. When multiple comparisons have been performed
Dunnett’s multiple comparison post hoc tests were performed. Statistical
significance is shown using the following nomenclature: ns p > 0.05, *p ≤
0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.
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